Cytora Stem Information

CYTORA is a clinical stage biotechnology stem cell company developing a unique class of medicines based on a novel and transformative patented platform stem cell technology - CytoraStem(TM). Our platform utilizes proprietary allogeneic human oral mucosal stem cells (hOMSCs)—a unique cell population with demonstrated regenerative potential, robustly supported by our clinical trials. Oral mucosal stem cells can be collected through minimally invasive procedures and exhibit favorable characteristics for tissue regeneration and wound healing. By scaling this revolutionary development into off-the-shelf (allogeneic) therapeutic doses, CYTORA is positioned to treat challenging diseases, including chronic wounds such as incurable diabetic foot ulcers (DFUs) and degenerative diseases such as Parkinson's disease, Multiple System Atrophy (MSA), and more. Clinical progress: Diabetic Foot Ulcers (DFUs): Successfully completed a Phase 1/2a clinical study. Multiple System Atrophy (MSA): Successfully completed a Phase 1 clinical study. Strategic Alliances: U.S. Expansion: CYTORA has established a comprehensive strategic partnership with Made Scientific and Zeo Scientifix to advance and commercialize our therapies in the United States. This alliance combines Made Scientific's world-class manufacturing expertise with Zeo's deep understanding of the U.S. regenerative medicine market setting the foundation for bringing Cytora’s innovative oral mucosal stem cell therapy to patients who urgently need new treatment options. Led by a pioneering scientific team at the forefront of regenerative medicine, CYTORA leverages years of dedicated research, robust patents, and deep industry experience. Our Mission: To establish off-the-shelf, hOMSC-based products as the global standard of care for patients facing devastating and challenging diseases. Our Vision: To transform healthcare, improve quality of life, and save the lives of millions of patients worldwide.